Page last updated: 2024-12-10

bn 50730

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

BN 50730: platelet activating factor antagonist; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID3033963
CHEMBL ID2105298
SCHEMBL ID1065775
MeSH IDM0182976

Synonyms (26)

Synonym
132579-32-9
lau8080
lau-8080
lau 8080
bn 50730
6-(2-chlorophenyl)-9-((4-methoxyphenyl)thiocarbamoyl)-1-methyl-7,8,9,10-tetrahydro-4h-pyrido(4',3'-4,5)thieno(3,2-f)(1,2,4)triazolo(4,3-a)(1,4)diazepine
bn-50730
bn50730
4h-pyrido(4',3'-4,5)thieno(3,2-f)(1,2,4)triazolo(4,3-a)(1,4)diazepine-9(8h)-carbothioamide, 6-(2-chlorophenyl)-7,10-dihydro-n-(4-methoxyphenyl)-1-methyl-
6-(o-chlorophenyl)-7,10-dihydro-1-methylthio-4h-pyrido(4',3':4,5)thieno(3,2-f)-s-triazolo(4,3-a)(1,4)diazepine-9(8h)-carboxy-p-anisidide
unii-4kgx1sty2n
rocepafant [inn]
132418-36-1
4kgx1sty2n ,
4h-pyrido(4',3':4,5)thieno(3,2-f)(1,2,4)triazolo(4,3-a)(1,4)diazepine-9(8h)-carbothioamide, 7,10-dihydro-6-(2-chlorophenyl)-n-(4-methoxyphenyl)-1-methyl-
rocepafant
CHEMBL2105298
SCHEMBL1065775
bn50730;bn-50730;bn 50730;lau8080;lau-8080;lau 8080
9-(2-chlorophenyl)-n-(4-methoxyphenyl)-3-methyl-17-thia-2,4,5,8,14-pentazatetracyclo[8.7.0.02,6.011,16]heptadeca-1(10),3,5,8,11(16)-pentaene-14-carbothioamide
9-(2-chlorophenyl)-n-(4-methoxyphenyl)-3-methyl-17-thia-2,4,5,8,14-pentazatetracyclo[8.7.0.02,6.011,16]heptadeca-1(10),3,5,8,11(16)-pentaene-14-carboximidothioic acid
Q27259885
DTXSID40869815
6-(2-chlorophenyl)-n-(4-methoxyphenyl)-1-methyl-7,10-dihydro-4h-pyrido[4',3':4,5]thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine-9(8h)-carbothioamide
AKOS040749357
4h-pyrido[4',3':4,5]thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine-9(8h)-carbothioamide, 6-(2-chlorophenyl)-7,10-dihydro-n-(4-methoxyphenyl)-1-methyl-

Research Excerpts

Treatment

Oral treatment with BN 50730 (10-20 mg kg-1, 1 h beforehand) suppressed the leucocyte accumulation and late eosinophilia observed 6 and 24 h after PAF. Treatment with Bn 50730 resulted in approximately 60- 80% reduction in ipsilateral tissue loss at both times.

ExcerptReferenceRelevance
"In BN 50730 treated mice (3 mg/kg) we also observed a significant reduction of the inflammation score (0.1 +/- 0.1 vs 2.5 +/- 0.2 in the untreated) and deposition of fibronectin."( A platelet activating factor receptor antagonist prevents the development of chronic arthritis in mice.
Egido, J; Gutierrez, S; Herrero-Beaumont, G; Miguélez, R; Palacios, I; Sánchez-Pernaute, O, 1999
)
0.82
"Oral treatment with BN 50730 (10-20 mg kg-1, 1 h beforehand) suppressed the leucocyte accumulation and late eosinophilia observed 6 and 24 h after PAF respectively, but did not modify the eosinophilia induced by leukotriene B4 (LTB4) or bradykinin."( Long-lasting inhibitory activity of the hetrazepinic BN 50730 on exudation and cellular alterations evoked by PAF and LPS.
Bozza, PT; Braquet, P; Castro-Faria-Neto, HC; Cordeiro, RS; e Silva, PM; Lagente, V; Martins, MA; Pasquale, C; Pires, AL; Rae, GA, 1994
)
0.85
"Treatment with BN 50730 resulted in no improvement and was no more effective than placebo in improving clinical and biological indices of RA activity. "( A double blind, placebo controlled study of a platelet activating factor antagonist in patients with rheumatoid arthritis.
Chermat-Izard, V; Hilliquin, P; Menkes, CJ, 1998
)
0.65
"Treatment with BN 50730 resulted in approximately 60- 80% reduction in ipsilateral tissue loss at both times."( Platelet-activating factor antagonist BN 50730 attenuates hypoxic-ischemic brain injury in neonatal rats.
Barks, JD; Eun, BL; Liu, XH, 2001
)
0.92

Dosage Studied

ExcerptRelevanceReference
" The PAF receptor antagonism with BN 50730 was overcome when 10-fold larger doses of PAF were administered and the dose-response curves for changes in lung resistance and dynamic compliance were shifted to the right in a parallel manner."( Influence of SK&F 95587 and BN 50730 on bronchoconstrictor responses in the cat.
Beckerman, RC; Bellan, JA; Braquet, P; Dyson, MC; Kadowitz, PJ; McNamara, DB; Minkes, RK; Wegmann, MJ, 1990
)
0.85
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (48)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's42 (87.50)18.2507
2000's5 (10.42)29.6817
2010's1 (2.08)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.21

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.21 (24.57)
Research Supply Index3.95 (2.92)
Research Growth Index4.16 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.21)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (4.08%)5.53%
Reviews4 (8.16%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other43 (87.76%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]